258 related articles for article (PubMed ID: 10887643)
1. Pentostatin treatment of cutaneous T-cell lymphoma.
Dearden C; Matutes E; Catovsky D
Oncology (Williston Park); 2000 Jun; 14(6 Suppl 2):37-40. PubMed ID: 10887643
[TBL] [Abstract][Full Text] [Related]
2. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.
Ho AD; Suciu S; Stryckmans P; De Cataldo F; Willemze R; Thaler J; Peetermans M; Döhner H; Solbu G; Dardenne M; Zittoun R
Semin Oncol; 2000 Apr; 27(2 Suppl 5):52-7. PubMed ID: 10877053
[TBL] [Abstract][Full Text] [Related]
3. Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies.
Foss FM
Semin Oncol; 2000 Apr; 27(2 Suppl 5):58-63. PubMed ID: 10877054
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series.
Tsimberidou AM; Giles F; Duvic M; Fayad L; Kurzrock R
Cancer; 2004 Jan; 100(2):342-9. PubMed ID: 14716770
[TBL] [Abstract][Full Text] [Related]
5. Pentostatin (Nipent) in T-cell lymphomas.
Kurzrock R
Semin Oncol; 2000 Apr; 27(2 Suppl 5):64-6. PubMed ID: 10877055
[TBL] [Abstract][Full Text] [Related]
6. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype.
Mercieca J; Matutes E; Dearden C; MacLennan K; Catovsky D
J Clin Oncol; 1994 Dec; 12(12):2588-93. PubMed ID: 7989933
[TBL] [Abstract][Full Text] [Related]
7. Clinical overview of pentostatin (Nipent) use in lymphoid malignancies.
Dearden CE; Matutes E; Catovsky D
Semin Oncol; 2000 Apr; 27(2 Suppl 5):22-6. PubMed ID: 10877047
[TBL] [Abstract][Full Text] [Related]
8. Deoxycoformycin in the treatment of mature T-cell leukaemias.
Dearden C; Matutes E; Catovsky D
Br J Cancer; 1991 Nov; 64(5):903-6. PubMed ID: 1931613
[TBL] [Abstract][Full Text] [Related]
9. Pentostatin in T-cell malignancies--a phase II trial of the EORTC. Leukemia Cooperative Group.
Ho AD; Suciu S; Stryckmans P; De Cataldo F; Willemze R; Thaler J; Peetermans M; Döhner H; Solbu G; Dardenne M; Zittoun R
Ann Oncol; 1999 Dec; 10(12):1493-8. PubMed ID: 10643542
[TBL] [Abstract][Full Text] [Related]
10. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma.
Gerami P; Wickless SC; Rosen S; Kuzel TM; Ciurea A; Havey J; Guitart J
J Am Acad Dermatol; 2008 Aug; 59(2):245-54. PubMed ID: 18486274
[TBL] [Abstract][Full Text] [Related]
11. Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes.
Dang NH; Hagemeister FB; Duvic M; Romaguera JE; Younes A; Jones D; Samuels B; Fayad LE; Pro B; Samaniego F; Sarris A; Goy A; McLaughlin P; Tong AT; Walker PL; Tiongson LP; Smith TL; Huh YO; Morimoto C; Rodriguez MA
Oncol Rep; 2003; 10(5):1513-8. PubMed ID: 12883733
[TBL] [Abstract][Full Text] [Related]
12. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations.
Kurzrock R; Pilat S; Duvic M
J Clin Oncol; 1999 Oct; 17(10):3117-21. PubMed ID: 10506607
[TBL] [Abstract][Full Text] [Related]
13. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
14. Pentostatin plus cyclophosphamide and bexarotene is an effective and safe combination in patients with mycosis fungoides/Sezary syndrome.
Calderon Cabrera C; de la Cruz Vicente F; Marín-Niebla A; Carrillo Cruz E; Rios Herranz E; Espigado Tocino I; Prats Martín C; Falantes JF; Martino Galiana ML; Perez-Simón JA
Br J Haematol; 2013 Jul; 162(1):130-2. PubMed ID: 23581433
[No Abstract] [Full Text] [Related]
15. Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma.
Greiner D; Olsen EA; Petroni G
J Am Acad Dermatol; 1997 Jun; 36(6 Pt 1):950-5. PubMed ID: 9204061
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study.
Johnston JB; Eisenhauer E; Wainman N; Corbett WE; Zaentz SD; Daeninck PJ
Semin Oncol; 2000 Apr; 27(2 Suppl 5):32-6. PubMed ID: 10877049
[TBL] [Abstract][Full Text] [Related]
17. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
18. Future directions for pentostatin (Nipent) usage in dermatology.
Heald P
Semin Oncol; 2000 Apr; 27(2 Suppl 5):3-8. PubMed ID: 10877044
[TBL] [Abstract][Full Text] [Related]
19. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
20. High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas.
Valencak J; Schmid K; Trautinger F; Wallnöfer W; Muellauer L; Soleiman A; Knobler R; Haitel A; Pehamberger H; Raderer M
J Dermatol Sci; 2011 Dec; 64(3):185-90. PubMed ID: 21937200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
